ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG

(EUZ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Eckert & Ziegler Strahlen und Medizintechnik : Hauck & Aufhäuser

03/30/2021 | 07:47am EDT

Eckert & Ziegler AG

Germany - High-tech Engineering

Buy (old: Buy)

Price target: EUR 80.00 (old: EUR 80.00)

Price:Bloomberg: Reuters:

EUR 69.15

EUZ GR EUZG.DE

Next result:Market cap: Enterprise Value:

tbdEUR 1,230.1 m EUR 1,151.8 m

Long-term growth story in early innings

Topic: EUZ's preliminary results for FY'20 confirmed the early sales and EPS indication.

The company also issued an outlook for FY'21E targeting "stable revenue" and an EPS of € 1.40 (+26% yoy). Due to one-time effects, the guidance is hard to interpret on a first glance and needs to be closely examined.

On a reported basis, EUZ expects sales to remain flat yoy in FY'21E. This, however, needs to be put in the context of divested non-core HDR business, which contributed roughly € 11m in sales. Adjusted for that, FY'21E sales are expected to grow by 7% yoy. Still, even the underlying 7% yoy sales growth looks conservative. Two reasons:

  • First, the Isotope Product division is said to recover to the pre-COVID level of c. € 10m net income, which would correspond to c. € 100m+ sales (+7% yoy).

  • Second, assuming sustained sales growth with radiopharmaceuticals (65% of Medical sales) of 20-30% p.a., this would imply up to 20% sales decline of the remainder of the Medical division. This is rather an unreasonable scenario given that this part of the Medical division recorder flat sales even during the pandemic year.

The EPS outlook of € 1.40 can be broken down into: € 1.30 underlying EPS and c.

€ 0.10 net positive one-off. Evidently, just like the sales outlook, this is rather a conservative forecast. Indeed, true to its prudent nature, the company does not include potential demand stemming from market launches of new radiopharmaceuticals. Yet, there's a few highly anticipated launches from Telix, Sirtex and from Novartis that should drive demand for radiopharmaceutical isotopes.

That being said, an underlying EPS of > € 1.30 should be well in reach in light of the

Isotope Products recovery and sustained growth with high-margin radiopharmaceuticals. Hence, we expect EUZ to upgrade its FY'21E EPS forecast in the course of the year.

Positive news flow should persist on the back of upcoming drug approvals from Telix, Sirtex and Novartis as well as GMP approval for n.c.a. Lu-177 production and potential engineering contacts for radiopharmaceutical infrastructure (e.g. production lines, etc.). All of that should translate into an even stronger growth in 2022E.

Action: Sales is reduced by € 11m following the HDR sale. A slightly lower 2021E EBIT reflects additional reorganization costs following the sale of the HDR business.

BUY with an unchanged PT of € 80 based on DCF.

Source: Company data, Hauck & Aufhäuser

High/low 52 weeks: 69.70 / 30.88 Price/Book Ratio: 9.9

Relative performance (SDAX):

Sales

EBIT

EPS

2020

old:

171.5

32.1

1.04

-

-

-

2021

old:

190.9

39.2

1.28

-5.9%

-3.6%

-3.7%

2022

old:

229.3

54.6

1.81

-5.7%

-

-

3 months

55.6 %

6 months

37.7 %

12 months

31.2 %

Changes in estimates

Key share data:

Number of shares: (in m pcs) 21.2

Authorised capital: (in € m) 0.6

Y/E 31.12 (EUR m)

2017

2018

2019

2020EP

2021E

2022E

2023E

Book value per share: (in €)

7.1

Sales

138.6

168.7

178.5

171.5

179.6

216.2

260.3

Ø trading volume: (12 months)

20,453

Sales growth

16 %

22 %

6 %

-4 %

5%

20 %

20 %

EBITDA

26.6

32.0

43.1

43.2

48.9

65.6

85.1

EBIT

18.0

23.4

32.1

32.1

37.8

54.5

75.1

Major shareholders:

Net income

14.7

16.1

22.0

22.1

26.2

38.2

53.0

Net debt

-56.0

-54.1

-78.9

-91.8

-104.2

-127.5

-156.9

Free float

67.8 %

Net gearing

-49.8 %

-44.1 %

-57.1 %

-61.3 %

-62.1 %

-64.5 %

-66.2 %

Founders

32.2 %

Net Debt/EBITDA

0.0

0.0

0.0

0.0

0.0

0.0

0.0

Eckert & Ziegler AG

0.1 %

EPS pro forma

2.19

3.12

1.03

1.04

1.24

1.80

2.50

CPS

3.54

2.53

1.41

0.95

1.14

1.39

1.87

DPS

0.80

1.20

0.34

0.35

0.41

0.60

0.83

Company description:

Dividend yield

1.4 %

2.1 %

0.6 %

0.6 %

0.7 %

1.0 %

1.4 %

Gross profit margin

46.1 %

44.1 %

48.8 %

49.2 %

50.5 %

52.5 %

53.1 %

EBITDA margin

19.2 %

18.9 %

24.2 %

25.2 %

27.2 %

30.3 %

32.7 %

EBIT margin

13.0 %

13.9 %

18.0 %

18.7 %

21.1 %

25.2 %

28.9 %

ROCE

13.8 %

17.6 %

22.5 %

22.6 %

26.6 %

25.9 %

25.4 %

EV/sales

1.8

1.5

6.5

6.7

6.3

5.2

4.2

EV/EBITDA

9.5

8.0

27.0

26.7

23.3

17.0

12.8

EV/EBIT

14.1

11.0

36.3

35.9

30.1

20.5

14.5

PER

21.4

15.4

53.6

52.5

43.6

29.2

23.2

Adjusted FCF yield

4.8 %

6.7 %

2.0 %

2.0 %

2.4 %

3.6 %

5.1 %

Source: Company data, Hauck & Aufhäuser Close price as of: 29.03.2021

Please refer to important disclosures at the end of the report

Produces and markets a wide range of industrial and medical applications featuring radioactive isotopes, including prostate seed implants, calibration standards and radiation afterloaders.

Financials

Profit and loss (EUR m)

2017

2018

2019

2020E

2021E

2022E

2023E

Sales

138.6

168.7

178.5

171.5

190.9

229.3

273.8

Sales growth

15.7 %

21.7 %

5.8 %

-3.9 %

11.3 %

20.1 %

19.4 %

Cost of sales

74.8

94.4

91.5

87.1

94.5

108.9

128.4

Gross profit

63.9

74.3

87.0

84.4

96.4

120.4

145.4

Sales and marketing

20.0

23.3

22.9

22.0

23.7

26.4

27.4

General and administration

23.9

26.9

27.6

26.5

29.0

33.9

37.2

Research and development

0.0

0.0

0.0

0.0

0.0

0.0

0.0

Other operating income

3.8

3.5

2.8

2.7

2.7

2.7

2.7

Other operating expenses

4.5

4.5

7.1

6.5

7.2

8.2

8.2

Unusual or infrequent items

-1.2

0.2

-0.2

0.0

0.0

0.0

0.0

EBITDA

26.6

32.0

43.1

43.2

50.3

65.7

85.4

Depreciation

8.6

8.6

11.1

11.1

11.1

11.1

10.0

EBITA

18.0

23.4

32.1

32.1

39.2

54.6

75.4

Amortisation of goodwill

0.0

0.0

0.0

0.0

0.0

0.0

0.0

Amortisation of intangible assets

0.0

0.0

0.0

0.0

0.0

0.0

0.0

Impairment charges

0.0

0.0

0.0

0.0

0.0

0.0

0.0

EBIT (inc revaluation net)

18.0

23.4

32.1

32.1

39.2

54.6

75.4

Interest income

0.3

0.2

0.3

0.3

0.3

0.3

0.3

Interest expenses

0.9

0.7

1.1

1.1

1.1

1.1

1.1

Other financial result

0.0

0.0

0.0

0.0

0.0

0.0

0.0

Financial result

-0.6

-0.5

-0.8

-0.8

-0.8

-0.8

-0.8

Recurring pretax income from continuing operations

17.3

22.9

31.2

31.3

38.4

53.8

74.5

Extraordinary income/loss

0.0

0.0

0.0

0.0

0.0

0.0

0.0

Earnings before taxes

17.3

22.9

31.2

31.3

38.4

53.8

74.5

Taxes

5.3

6.0

8.8

8.8

10.8

15.1

20.9

Net income from continuing operations

12.0

16.9

22.5

22.5

27.6

38.7

53.6

Result from discontinued operations (net of tax)

3.1

0.0

0.0

0.0

0.0

0.0

0.0

Net income

15.1

16.9

22.5

22.5

27.6

38.7

53.6

Minority interest

0.4

0.8

0.5

0.5

0.5

0.5

0.5

Net profit (reported)

14.7

16.1

22.0

22.1

27.2

38.2

53.2

Average number of shares

5.3

5.2

21.2

21.2

21.2

21.2

21.2

EPS reported

2.78

3.12

1.04

1.04

1.28

1.81

2.51

Profit and loss (common size)

2017

2018

2019

2020E

2021E

2022E

2023E

Sales

100.0 %

100.0 %

100.0 %

100.0 %

100.0 %

100.0 %

100.0 %

Cost of sales

53.9 %

55.9 %

51.2 %

50.8 %

49.5 %

47.5 %

46.9 %

Gross profit

46.1 %

44.1 %

48.8 %

49.2 %

50.5 %

52.5 %

53.1 %

Sales and marketing

14.4 %

13.8 %

12.8 %

12.8 %

12.4 %

11.5 %

10.0 %

General and administration

17.3 %

15.9 %

15.4 %

15.4 %

15.2 %

14.8 %

13.6 %

Research and development

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

Other operating income

2.7 %

2.1 %

1.6 %

1.6 %

1.4 %

1.2 %

1.0 %

Other operating expenses

3.2 %

2.6 %

4.0 %

3.8 %

3.8 %

3.6 %

3.0 %

Unusual or infrequent items

neg.

0.1 %

neg.

0.0 %

0.0 %

0.0 %

0.0 %

EBITDA

19.2 %

18.9 %

24.2 %

25.2 %

26.3 %

28.6 %

31.2 %

Depreciation

6.2 %

5.1 %

6.2 %

6.5 %

5.8 %

4.8 %

3.7 %

EBITA

13.0 %

13.9 %

18.0 %

18.7 %

20.5 %

23.8 %

27.5 %

Amortisation of goodwill

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

Amortisation of intangible assets

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

Impairment charges

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

EBIT (inc revaluation net)

13.0 %

13.9 %

18.0 %

18.7 %

20.5 %

23.8 %

27.5 %

Interest income

0.2 %

0.1 %

0.2 %

0.2 %

0.2 %

0.1 %

0.1 %

Interest expenses

0.6 %

0.4 %

0.6 %

0.6 %

0.6 %

0.5 %

0.4 %

Other financial result

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

Financial result

neg.

neg.

neg.

neg.

neg.

neg.

neg.

Recurring pretax income from continuing operations

12.5 %

13.6 %

17.5 %

18.2 %

20.1 %

23.5 %

27.2 %

Extraordinary income/loss

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

Earnings before taxes

12.5 %

13.6 %

17.5 %

18.2 %

20.1 %

23.5 %

27.2 %

Tax rate

30.7 %

26.2 %

28.1 %

28.1 %

28.1 %

28.1 %

28.1 %

Net income from continuing operations

8.7 %

10.0 %

12.6 %

13.1 %

14.5 %

16.9 %

19.6 %

Result from discontinued operations (net of tax)

2.2 %

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

Net income

10.9 %

10.0 %

12.6 %

13.1 %

14.5 %

16.9 %

19.6 %

Minority interest

0.3 %

0.4 %

0.3 %

0.3 %

0.2 %

0.2 %

0.2 %

Net profit (reported)

10.6 %

9.6 %

12.3 %

12.9 %

14.2 %

16.7 %

19.4 %

Source: Company data, Hauck & Aufhäuser

2

Balance sheet (EUR m)

2017

2018

2019

2020E

2021E

2022E

2023E

Intangible assets

51.4

52.5

51.9

51.9

51.9

51.9

51.9

Property, plant and equipment

33.8

36.9

40.0

36.2

40.1

36.3

32.8

Financial assets

3.2

3.5

5.2

8.4

8.4

8.4

8.4

FIXED ASSETS

88.5

93.0

97.1

96.5

100.4

96.6

93.1

Inventories

26.8

28.8

31.2

35.0

39.0

44.1

52.7

Accounts receivable

24.3

28.3

29.5

30.1

33.5

40.2

48.0

Other current assets

10.9

14.9

26.6

26.6

26.6

26.6

26.6

Liquid assets

57.7

54.2

78.9

91.8

101.3

123.9

153.2

Deferred taxes

8.8

9.9

10.9

0.0

0.0

0.0

0.0

Deferred charges and prepaid expenses

0.0

0.0

0.0

0.0

0.0

0.0

0.0

CURRENT ASSETS

128.5

136.1

177.1

183.5

200.4

234.8

280.5

TOTAL ASSETS

217.0

229.1

274.2

280.0

300.8

331.4

373.6

SHAREHOLDERS EQUITY

112.3

122.6

138.2

149.7

168.8

198.4

238.0

MINORITY INTEREST

5.2

1.2

1.2

1.2

1.2

0.0

0.0

Long-term debt

0.0

0.0

0.0

0.0

0.0

0.0

0.0

Provisions for pensions and similar obligations

11.7

11.4

13.5

13.5

13.5

13.5

13.5

Other provisions

48.7

55.1

66.4

61.9

63.2

64.4

65.7

Non-current liabilities

60.4

66.5

79.9

75.4

76.7

77.9

79.2

short-term liabilities to banks

1.7

0.0

0.0

0.0

0.0

0.0

0.0

Accounts payable

4.5

6.5

4.5

6.0

6.5

7.5

8.8

Advance payments received on orders

5.9

4.1

12.0

12.0

12.0

12.0

12.0

Other liabilities (incl. from lease and rental contracts)

17.3

17.4

35.6

35.6

35.6

35.6

35.6

Deferred taxes

6.4

7.1

2.8

0.0

0.0

0.0

0.0

Deferred income

3.3

3.6

0.0

0.0

0.0

0.0

0.0

Current liabilities

39.1

38.8

54.9

53.5

54.0

55.0

56.4

TOTAL LIABILITIES AND SHAREHOLDERS EQUITY

217.0

229.1

274.2

280.0

300.8

331.4

373.6

Balance sheet (common size)

2017

2018

2019

2020E

2021E

2022E

2023E

Intangible assets

23.7 %

22.9 %

18.9 %

18.5 %

17.3 %

15.7 %

13.9 %

Property, plant and equipment

15.6 %

16.1 %

14.6 %

12.9 %

13.3 %

11.0 %

8.8 %

Financial assets

1.5 %

1.5 %

1.9 %

3.0 %

2.8 %

2.5 %

2.2 %

FIXED ASSETS

40.8 %

40.6 %

35.4 %

34.5 %

33.4 %

29.2 %

24.9 %

Inventories

12.3 %

12.6 %

11.4 %

12.5 %

13.0 %

13.3 %

14.1 %

Accounts receivable

11.2 %

12.4 %

10.8 %

10.7 %

11.1 %

12.1 %

12.9 %

Other current assets

5.0 %

6.5 %

9.7 %

9.5 %

8.8 %

8.0 %

7.1 %

Liquid assets

26.6 %

23.7 %

28.8 %

32.8 %

33.7 %

37.4 %

41.0 %

Deferred taxes

4.1 %

4.3 %

4.0 %

0.0 %

0.0 %

0.0 %

0.0 %

Deferred charges and prepaid expenses

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

CURRENT ASSETS

59.2 %

59.4 %

64.6 %

65.5 %

66.6 %

70.8 %

75.1 %

TOTAL ASSETS

100.0 %

100.0 %

100.0 %

100.0 %

100.0 %

100.0 %

100.0 %

SHAREHOLDERS EQUITY

51.8 %

53.5 %

50.4 %

53.5 %

56.1 %

59.9 %

63.7 %

MINORITY INTEREST

2.4 %

0.5 %

0.5 %

0.4 %

0.4 %

0.0 %

0.0 %

Long-term debt

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

Provisions for pensions and similar obligations

5.4 %

5.0 %

4.9 %

4.8 %

4.5 %

4.1 %

3.6 %

Other provisions

22.4 %

24.0 %

24.2 %

22.1 %

21.0 %

19.4 %

17.6 %

Non-current liabilities

27.8 %

29.0 %

29.1 %

26.9 %

25.5 %

23.5 %

21.2 %

short-term liabilities to banks

0.8 %

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

Accounts payable

2.1 %

2.8 %

1.6 %

2.1 %

2.2 %

2.3 %

2.4 %

Advance payments received on orders

2.7 %

1.8 %

4.4 %

4.3 %

4.0 %

3.6 %

3.2 %

Other liabilities (incl. from lease and rental contracts)

8.0 %

7.6 %

13.0 %

12.7 %

11.8 %

10.7 %

9.5 %

Deferred taxes

3.0 %

3.1 %

1.0 %

0.0 %

0.0 %

0.0 %

0.0 %

Deferred income

1.5 %

1.6 %

0.0 %

0.0 %

0.0 %

0.0 %

0.0 %

Current liabilities

18.0 %

16.9 %

20.0 %

19.1 %

18.0 %

16.6 %

15.1 %

TOTAL LIABILITIES AND SHAREHOLDERS EQUITY

100.0 %

100.0 %

100.0 %

100.0 %

100.0 %

100.0 %

100.0 %

Source: Company data, Hauck & Aufhäuser

3

Cash flow statement (EUR m)

2017

2018

2019

2020E

2021E

2022E

2023E

Net profit/loss

15.1

16.9

22.5

22.5

27.6

38.7

53.6

Depreciation of fixed assets (incl. leases)

8.6

8.6

11.1

11.1

11.1

11.1

10.0

Amortisation of goodwill

0.0

0.0

0.0

0.0

0.0

0.0

0.0

Amortisation of intangible assets

0.0

0.0

0.0

0.0

0.0

0.0

0.0

Others

5.5

2.8

10.6

0.0

0.0

0.0

0.0

Cash flow from operations before changes in w/c

29.3

28.2

44.1

33.6

38.7

49.8

63.6

Increase/decrease in inventory

-1.7

0.7

-2.2

-3.8

-4.0

-5.1

-8.6

Increase/decrease in accounts receivable

-1.1

-4.0

-1.2

-0.6

-3.4

-6.7

-7.8

Increase/decrease in accounts payable

-1.9

2.0

-0.4

1.5

0.5

1.0

1.3

Increase/decrease in other working capital positions

2.2

-5.7

0.0

0.0

0.0

0.0

0.0

Increase/decrease in working capital

-2.5

-7.0

-3.7

-2.9

-6.9

-10.9

-15.0

Cash flow from operating activities

26.8

21.2

40.4

30.7

31.8

38.9

48.6

CAPEX

4.2

6.1

7.3

7.3

15.0

7.3

6.5

Payments for acquisitions

5.5

2.1

0.9

0.0

0.0

0.0

0.0

Financial investments

0.5

0.0

0.0

3.2

0.0

0.0

0.0

Income from asset disposals

15.2

-2.5

2.5

0.0

0.0

0.0

0.0

Cash flow from investing activities

5.1

-10.7

-5.7

-10.5

-15.0

-7.3

-6.5

Cash flow before financing

31.9

10.5

34.7

20.3

16.8

31.6

42.1

Increase/decrease in debt position

-5.3

-1.7

-2.7

0.0

0.0

0.0

0.0

Purchase of own shares

0.0

8.6

0.0

0.0

0.0

0.0

0.0

Capital measures

0.0

0.0

0.0

0.0

0.0

0.0

0.0

Dividends paid

3.5

4.1

6.2

7.3

7.4

9.1

12.7

Others

-1.2

-0.2

-1.7

0.0

0.0

0.0

0.0

Effects of exchange rate changes on cash

-0.8

0.6

0.5

0.0

0.0

0.0

0.0

Cash flow from financing activities

-10.0

-14.6

-10.5

-7.3

-7.4

-9.1

-12.7

Increase/decrease in liquid assets

21.1

-3.5

24.7

13.0

9.5

22.6

29.3

Liquid assets at end of period

57.7

54.2

78.9

91.8

101.3

123.9

153.2

Source: Company data, Hauck & Aufhäuser

Regional split (EUR m)

2017

2018

2019

2020E

2021E

2022E

2023E

Domestic

0.0

0.0

0.0

0.0

0.0

0.0

0.0

yoy change

n/a

n/a

n/a

n/a

n/a

n/a

n/a

Rest of Europe

84.9

96.8

110.4

125.9

143.5

163.6

186.5

yoy change

14.0 %

14.0 %

14.0 %

14.0 %

14.0 %

14.0 %

14.0 %

NAFTA

53.0

60.9

70.1

80.6

92.7

106.6

122.5

yoy change

15.0 %

15.0 %

15.0 %

15.0 %

15.0 %

15.0 %

15.0 %

Asia Pacific

15.8

17.9

20.2

22.9

25.8

29.2

33.0

yoy change

13.0 %

13.0 %

13.0 %

13.0 %

13.0 %

13.0 %

13.0 %

Rest of world

-15.1

-7.0

-22.2

-57.8

-71.0

-70.0

-68.1

yoy change

neg.

neg.

neg.

neg.

neg.

neg.

neg.

TTL

138.6

168.7

178.5

171.5

190.9

229.3

273.8

yoy change

15.7 %

21.7 %

5.8 %

-3.9 %

11.3 %

20.1 %

19.4 %

Source: Company data, Hauck & Aufhäuser

4

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Eckert & Ziegler AG published this content on 30 March 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 March 2021 11:46:05 UTC.


© Publicnow 2021
All news about ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG
05/12Eckert & Ziegler Strahlen- und Medizintechnik AG Reports Earnings Results for the First..
CI
05/12Eckert & Ziegler with Sales Growth in the First Quarter of 2022
EQ
05/12Eckert & Ziegler Strahlen- und Medizintechnik AG Reaffirms Earnings Guidance for the Ye..
CI
05/11Eckert & Ziegler Cooperates with Czech Research Center UJF to Produce Pharmaceutical Al..
EQ
05/11Eckert & Ziegler Cooperates with Czech Research Center UJF to Produce Pharmaceutical Al..
CI
04/12ECKERT & ZIEGLER STRAHLEN UND MEDIZI : Report of the Supervisory Board
PU
04/12ECKERT & ZIEGLER STRAHLEN UND MEDIZI : Proposal on the appropriation of net income
PU
04/11ECKERT & ZIEGLER : Hauck & Aufhauser remains its Buy rating
MD
04/11ECKERT & ZIEGLER STRAHLEN UND MEDIZI : Hauck & Aufhäuser
PU
04/08ECKERT & ZIEGLER : Radboud University Medical Center Netherlands to Image First Patient wi..
EQ
More news
Analyst Recommendations on ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG
More recommendations
Financials
Sales 2022 205 M 216 M 216 M
Net income 2022 30,7 M 32,3 M 32,3 M
Net cash 2022 55,7 M 58,7 M 58,7 M
P/E ratio 2022 28,8x
Yield 2022 1,17%
Capitalization 890 M 938 M 938 M
EV / Sales 2022 4,07x
EV / Sales 2023 3,91x
Nbr of Employees 866
Free-Float 67,1%
Chart ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG
Duration : Period :
Eckert & Ziegler Strahlen- und Medizintechnik AG Technical Analysis Chart | EUZ | DE0005659700 | MarketScreener
Technical analysis trends ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 42,90 €
Average target price 152,00 €
Spread / Average Target 254%
EPS Revisions
Managers and Directors
Andreas Eckert Chairman-Executive Board
Wolfgang Maennig Chairman-Supervisory Board
Helmut Grothe Vice Chairman-Supervisory Board
Albert Rupprecht Member-Supervisory Board
Edgar Löffler Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG-54.41%938
JOHNSON & JOHNSON4.53%470 547
PFIZER, INC.-13.06%288 063
ABBVIE INC.14.31%273 513
ELI LILLY AND COMPANY9.12%271 308
ROCHE HOLDING AG-14.97%263 868